September 14, 2025

Understanding hypertrophic cardiomyopathy and its regulation by myosin drugs.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Molecular insights reveal how myosin drugs modulate phosphate release in hypertrophic cardiomyopathy, indicating potential treatment avenues.

The R190T mutation in β-cardiac myosin destabilizes the prepowerstroke state, triggering rapid phosphate release.
Analysis of the phosphate release barrier demonstrates how myosin drugs alter cardiac myosin function in HCM.
Different drug effects on myosin highlight new therapeutic strategies for addressing hypertrophic cardiomyopathy challenges.
Multiscale approaches helped uncover vital mechanisms affecting the myosin cycle in hypertrophic cardiomyopathy cases.

Halder et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Molecular insights reveal how myosin drugs modulate phosphate release in hypertrophic cardiomyopathy, indicating potential treatment avenues.